Cargando…

Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare

Saracatinib/AZD0530 (SAR), a Src tyrosine kinase inhibitor, mitigates seizure-induced brain pathology in epilepsy models upon repeated oral dosing. However, repeated dosing is stressful and can be challenging in some seizing animals. To overcome this issue, we have incorporated SAR-in-Diet and compa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasanthi, Suraj S., Massey, Nyzil, Nair, Suresh N., Mochel, Jonathan P., Showman, Lucas, Thippeswamy, Thimmasettappa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Veterinary Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666625/ https://www.ncbi.nlm.nih.gov/pubmed/38026620 http://dx.doi.org/10.3389/fvets.2023.1297221

Ejemplares similares

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy
por: Sharma, Shaunik, et al.
Publicado: (2021)

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

1400 W, a selective inducible nitric oxide synthase inhibitor, mitigates early neuroinflammation and nitrooxidative stress in diisopropylfluorophosphate-induced short-term neurotoxicity rat model
por: Massey, Nyzil, et al.
Publicado: (2023)

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015)

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
por: Baird, Kristin, et al.
Publicado: (2020)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

Gut dysbiosis following organophosphate, diisopropylfluorophosphate (DFP), intoxication and saracatinib oral administration
por: Gage, Meghan, et al.
Publicado: (2022)

DFP-Induced Status Epilepticus Severity in Mixed-Sex Cohorts of Adult Rats Housed in the Same Room: Behavioral and EEG Comparisons
por: Rao, Nikhil S., et al.
Publicado: (2022)

The effects of Src tyrosine kinase inhibitor, saracatinib, on the markers of epileptogenesis in a mixed-sex cohort of adult rats in the kainic acid model of epilepsy
por: Rao, Nikhil S., et al.
Publicado: (2023)

Differential Impact of Severity and Duration of Status Epilepticus, Medical Countermeasures, and a Disease-Modifier, Saracatinib, on Brain Regions in the Rat Diisopropylfluorophosphate Model
por: Gage, Meghan, et al.
Publicado: (2021)

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
por: van Dyck, Christopher H., et al.
Publicado: (2019)

Disease-modifying effects of a glial-targeted inducible nitric oxide synthase inhibitor (1400W) in mixed-sex cohorts of a rat soman (GD) model of epilepsy
por: Vasanthi, Suraj S., et al.
Publicado: (2023)

Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress
por: Gage, Meghan, et al.
Publicado: (2021)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling
por: Zhao, Yi, et al.
Publicado: (2017)

Synergistic effect of STAT3-targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo
por: Liu, Qingjun, et al.
Publicado: (2019)

Disease-Modifying Effects of a Glial-targeted Inducible Nitric Oxide Synthase Inhibitor (1400W) in Mixed-sex Cohorts of a Rat Soman (GD) Model of Epilepsy
por: Vasanthi, Suraj S., et al.
Publicado: (2023)

Soman (GD) Rat Model to Mimic Civilian Exposure to Nerve Agent: Mortality, Video-EEG Based Status Epilepticus Severity, Sex Differences, Spontaneously Recurring Seizures, and Brain Pathology
por: Gage, Meghan, et al.
Publicado: (2022)

Sex‐based structural and functional MRI outcomes in the rat brain after soman (GD) exposure‐induced status epilepticus
por: Gage, Meghan, et al.
Publicado: (2023)

The Academic, Societal and Animal Welfare Benefits of Open Science for Animal Science
por: Nawroth, Christian, et al.
Publicado: (2022)

Peripheral and central effects of NADPH oxidase inhibitor, mitoapocynin, in a rat model of diisopropylfluorophosphate (DFP) toxicity
por: Meyer, Christina, et al.
Publicado: (2023)

Pharmacokinetics of Oral Prednisone at Various Doses in Dogs: Preliminary Findings Using a Naïve Pooled-Data Approach
por: Sebbag, Lionel, et al.
Publicado: (2020)

Tear Film Pharmacokinetics and Systemic Absorption Following Topical Administration of 1% Prednisolone Acetate Ophthalmic Suspension in Dogs
por: Sebbag, Lionel, et al.
Publicado: (2020)

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
por: Cawley, Jacob R., et al.
Publicado: (2022)

“Cattle Welfare Is Basically Human Welfare”: Workers' Perceptions of ‘Animal Welfare' on Two Dairies in China
por: Chen, Maria, et al.
Publicado: (2022)

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
por: Williams, Eleanor, et al.
Publicado: (2021)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
por: Olivarez, Jeff D., et al.
Publicado: (2023)

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration
por: Olivarez, Jeff D., et al.
Publicado: (2020)

Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs
por: Wang, Jianzhong, et al.
Publicado: (2019)

In vitro Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs
por: Musser, Margaret L., et al.
Publicado: (2019)

Editorial: Wildlife Welfare
por: Berg, Charlotte, et al.
Publicado: (2020)

Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
por: Warner, Rochelle, et al.
Publicado: (2020)

Advantages of Repeated Low Dose against Single High Dose of Kainate in C57BL/6J Mouse Model of Status Epilepticus: Behavioral and Electroencephalographic Studies
por: Tse, Karen, et al.
Publicado: (2014)

Corrigendum: Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
por: Warner, Rochelle, et al.
Publicado: (2021)

Choice, control, and animal welfare: definitions and essential inquiries to advance animal welfare science
por: Englund, Maisy D., et al.
Publicado: (2023)

Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
por: Wang, Jianzhong, et al.
Publicado: (2020)

Influence of Pyrexia on Pharmacokinetics of Azithromycin and Its Interaction With Tolfenamic Acid in Goats
por: Mechery, Sini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lpaca8krgm9k2ca892vd7ius85